Unicycive Therapeutics (UNCY) News Today

Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is facing continued negative sentiment as multiple securities law firms publicize a pending shareholder class-action lawsuit. The legal overhang appears to be the primary reason the stock has come under pressure.

• Negative Sentiment: Several firms, including Kaplan Fox, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and Faruqi & Faruqi, reminded investors that a class action has been filed against Unicycive and certain officers. The case covers investors who purchased securities from December 29, 2025, through June 29, 2026, with November 2, 2026, set as the deadline to seek lead-plaintiff status. Kaplan Fox class action notice
• Negative Sentiment: The lawsuit-related notices allege that Unicycive misled investors about the timing of an FDA decision for oxylanthanum carbonate and the potential commercial launch of the kidney-disease treatment. The allegations also claim the company had not inspected a third-party manufacturing facility that had previously contributed to a Complete Response Letter. These claims have not been proven in court. Unicycive shareholder alert
• Negative Sentiment: The volume of law-firm announcements over the past two days increases the visibility of potential litigation costs, regulatory and execution risks, and uncertainty surrounding Unicycive’s lead drug candidate. One notice cited a 39.1% share-price decline on June 30 following unusually heavy trading, intensifying investor concern. Levi and Korsinsky lawsuit reminder